Zepbound for Sleep Apnea: What the FDA Approved
The FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, together with diet and increased physical activity.
Timeline
- December 20, 2024: FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity.
- Clinical studies: Participants with obesity and sleep apnea received tirzepatide or placebo alongside lifestyle measures.
- Ongoing care: Treatment decisions still require diagnosis, prescribing and follow-up by a qualified clinician.
The US Food and Drug Administration approved Zepbound, the brand name for tirzepatide, to treat moderate to severe obstructive sleep apnea in adults with obesity. The approved use is alongside a reduced-calorie diet and increased physical activity. It was the first medication approved specifically for this indication. [1][2]
Obstructive sleep apnea occurs when the upper airway repeatedly narrows or closes during sleep, producing breathing interruptions and drops in oxygen. Body weight can contribute to airway obstruction, but sleep apnea has multiple anatomical and physiological factors. The approval does not redefine every case as a weight problem. [1]
FDA based the decision on two randomized studies in adults with obesity and moderate to severe obstructive sleep apnea. One included participants using positive airway pressure therapy and the other included participants unable or unwilling to use it. Tirzepatide reduced the apnea-hypopnea index compared with placebo, and many participants lost weight. [1][2]
The indication is not for mild sleep apnea, people without obesity, or children. A prescription requires an individual medical assessment. The label includes dosing, contraindications, warnings and adverse reactions that cannot be reduced to the headline result of the trials. [2]
Positive airway pressure devices remain an established treatment. A patient should not stop CPAP or another therapy because of the medication approval without speaking to the treating clinician. Follow-up sleep testing, symptom review and management of cardiovascular or metabolic risks may still be needed. [1][2]
Zepbound is given by weekly injection and is also approved for chronic weight management in certain patients. Insurance coverage and supply do not follow automatically from an FDA approval. Patients should verify the exact indication, prior-authorization rules and out-of-pocket cost with the prescriber and insurer. [1][2]
Safety considerations in the prescribing information include gastrointestinal effects and other warnings that require clinical review. Tirzepatide also has important limitations and is not interchangeable with an informal compounded product or another medicine merely because it targets a similar pathway. Patients should use the exact prescribed product and obtain urgent care for a serious reaction. [2]